The mutations were more frequent in the relapse tumor setting during ongoing treatment, further supporting that testing of PIK3CA mutation status for PI3K inhibitor treatment should be carried out on the advanced tumor specimen for treatment in the advanced setting. Here, PIK3CA is linked to neoplasm.